T. Rowe Price Investment Management, Inc. 13D and 13G filings for Ionis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-07 11:55 am Purchase |
2025-01-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Investment Management, Inc. | 15,851,863 10.000% |
1,683,747 (+11.88%) |
Filing |
| 2024-11-14 1:28 pm Purchase |
2024-09-30 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Investment Management, Inc. | 14,168,116 9.000% |
966,663 (+7.32%) |
Filing |
| 2024-02-14 10:04 am Purchase |
2023-12-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Investment Management, Inc. | 13,201,453 9.200% |
1,523,194 (+13.04%) |
Filing |
| 2023-02-14 12:40 pm Purchase |
2022-12-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Investment Management, Inc. | 11,678,259 8.200% |
11,678,259 (New Position) |
Filing |